Mineral and bone status in French maintenance hemodialysis patients: A comparison of June 2005 and June 2008;Évolution de la prise en charge de la maladie osseuse et minérale des patients hémodialysés en France entre juin 2005 et juin 2008

Nephrologie et Therapeutique

Volumn 6, Issue 1, 2010, Pages 11-20

  Pelletier, Solenne ^a   Roth, Hubert ^b   Bouchet, Jean Louis ^c   Drueke, Tilman ^d   Hannedouche, Thierry ^e   London, Gérard ^f   Fouque, Denis ^a,g  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c CLINIQUE SAINT AUGUSTIN   (France)

^d INSERM   (France)

^e UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^f Hopital Manhes   (France)

^g UNIVERSITÉ LYON 1   (France)

Author keywords

Calcium; Hemodialysis; Metabolism; Parathyroid hormone; Phosphate

Indexed keywords

25 HYDROXYVITAMIN D; ALFACALCIDOL; CALCITRIOL; CALCIUM; CALCIUM PHOSPHATE; CINACALCET; LANTHANUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE; SEVELAMER; VITAMIN D DERIVATIVE;

AGED; ARTICLE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPOCALCEMIA; HYPOPHOSPHATEMIA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PROGNOSIS; VITAMIN BLOOD LEVEL; BONE; CLINICAL TRIAL; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; FRANCE; METABOLISM; MULTICENTER STUDY; RENAL REPLACEMENT THERAPY; TIME;

AGED; BONE AND BONES; CALCIUM; CROSS-SECTIONAL STUDIES; FEMALE; FRANCE; HUMANS; MALE; PHOSPHATES; RENAL DIALYSIS; TIME FACTORS;

EID: 77149164440     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nephro.2009.09.001     Document Type: Article

References (13)

1. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(4 Suppl 3):S1-201.
2. Young E.W., et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 67 3 (2005) 1179-1187
3. Moe S., et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69 11 (2006) 1945-1953
4. Raggi P., and Kleerekoper M. Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease. Clin J Am Soc Nephrol 3 3 (2008) 836-843
5. London G.M., et al. Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens 14 6 (2005) 525-531
6. Moe S.M., and Chen N.X. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 19 2 (2008) 213-216
7. Couchoud C, et al. Rapport annuel 2005 du Réseau, épidémiologie, information, néphrologie « REIN ». Agence de biomédecine 2005, http://www.agence-biomedecine.fr/article/142.
8. Couchoud C, et al. Rapport annuel 2007 du Réseau, épidémiologie, information, néphrologie « REIN ». Agence de biomédecine 2007, http://www.agence-biomedecine.fr/article/142.
9. Fouque D., et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 73 4 (2008) 391-398
10. Malluche H.H., Mawad H., and Monier-Faugere M.C. Effects of treatment of renal osteodystrophy on bone histology. Clin J Am Soc Nephrol 3 Suppl 3 (2008) S157-S163
11. Alfrey A.C., LeGendre G.R., and Kaehny W.D. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 294 4 (1976) 184-188
12. Aloia J.F., et al. Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration. Am J Clin Nutr 87 6 (2008) 1952-1958
13. Cannata-Andia J.B., et al. Current management of secondary hyperparathyroidism: a multicenter observational study (COSMOS). J Nephrol 21 3 (2008) 290-298